Affinage

TCF7L1

Transcription factor 7-like 1 · UniProt Q9HCS4

Length
588 aa
Mass
62.6 kDa
Annotated
2026-06-10
28 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TCF7L1 is a sequence-specific HMG-box transcription factor that functions primarily as a Wnt/β-catenin-responsive repressor controlling pluripotency exit, lineage specification, and tumor cell behavior (PMID:23810553, PMID:36869101). In the absence of Wnt, it occupies TCF binding elements at target promoters and represses transcription; Wnt activation inactivates TCF7L1 chiefly by stripping it from DNA rather than converting it to a coactivator, an event that is necessary and sufficient to account for the TCF7L1–β-catenin interaction in vivo (PMID:23810553). DNA-displaced TCF7L1 is then destabilized by a convergent set of post-translational mechanisms: β-catenin recruits casein kinase 2 (Csnk2α1) to phosphorylate TCF7L1, the adaptor Tbl1 (Tbl1x) translocates to the nucleus with β-catenin to promote its ubiquitylation, and the E3 ligase RNF2 ubiquitinates TCF7L1 to set the threshold and termination of Wnt signaling (PMID:31987502, PMID:38639717, PMID:37957244). Independent of β-catenin, TCF7L1 stability is tuned by MEK/ERK-driven phosphorylation downstream of IGF and by O-GlcNAcylation (PMID:31322782, PMID:41930151). In stem and embryonic cells, TCF7L1 repressor activity restrains naive and formative pluripotency genes (including Otx2 and Lef1) and Nanog to drive pluripotency exit and primitive endoderm specification and to enable timely mesoderm and endoderm commitment, the latter through de-repression of the pioneer factor FoxA2 (PMID:36869101, PMID:26675138, PMID:23487311, PMID:31322782). TCF7L1 also acts as a β-catenin-independent transactivator in defined settings, promoting cardiomyocyte differentiation and activating Klf4 (PMID:30326964, PMID:29336356). Across cancers it governs target genes that include the tumor suppressor EPHB3, LCN2, LGR5, GAS1, IL-8/CXCR2, and androgen receptor, with context-dependent pro- and anti-tumor effects (PMID:27333864, PMID:28467300, PMID:36833408, PMID:38816533, PMID:34799554, PMID:41930151).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2013 High

    Established the core logic of how β-catenin neutralizes TCF7L1: it was unknown whether β-catenin converts TCF7L1 into an activator or simply inactivates it, and genetics showed inactivation by DNA displacement and degradation is the sole required output.

    Evidence Co-IP, DNA-binding assays, and mouse knockout/knock-in epistasis

    PMID:23810553

    Open questions at the time
    • Did not identify the degradation machinery acting on displaced TCF7L1
    • Did not resolve which target genes depend on this switch in vivo
  2. 2013 Medium

    Defined a developmental requirement for TCF7L1 repressor activity, showing it is needed in pluripotent epiblast for timely lineage specification rather than for primitive streak induction per se.

    Evidence Tcf7l1 knockout mouse embryo phenotyping and lineage marker analysis

    PMID:23487311

    Open questions at the time
    • Direct repressed targets driving the mesoderm delay not enumerated
    • Did not separate repressor versus structural roles
  3. 2015 High

    Connected Wnt input to a specific endoderm program, showing β-catenin reduces TCF7L1 DNA binding while cMyc lowers its mRNA, jointly de-repressing the pioneer factor FoxA2.

    Evidence GSK3 inhibition, Tcf7l1-null ESCs, ChIP, qRT-PCR, and rescue

    PMID:26675138

    Open questions at the time
    • Relative contribution of protein- versus mRNA-level control unquantified
    • FoxA2 downstream endoderm program not fully mapped
  4. 2015 Medium

    Identified a corepressor-displacement mechanism, showing Jmjd6 binds TCF7L1 at its Groucho-binding region to evict Groucho and de-repress targets.

    Evidence Co-IP, reporter assays, and morpholino loss-of-function in Xenopus

    PMID:26157142

    Open questions at the time
    • Whether Jmjd6 enzymatic activity is required is unresolved
    • Endogenous target genes affected not defined
  5. 2014 Medium

    Placed TCF7L1 within a transcriptional hierarchy by identifying Sox4 as a direct upstream activator of TCF7L1 in BCR-ABL+ ALL, with TCF7L1 as a key effector of Sox4-driven proliferation.

    Evidence Microarray, Sox4 ChIP at the Tcf7l1 locus, knockdown, and ectopic-rescue leukemia assays

    PMID:24997151

    Open questions at the time
    • TCF7L1 target genes mediating leukemic proliferation not identified
    • Wnt dependence of this axis untested
  6. 2016 Medium

    Showed TCF7L1 buffers β-catenin/TCF output in colorectal cancer, with loss activating the tumor suppressor EPHB3 to limit growth.

    Evidence TCF7L1 knockdown/knockout in HCT116, xenografts, and EPHB3 epistasis rescue

    PMID:27333864

    Open questions at the time
    • Direct EPHB3 promoter occupancy not shown here
    • Partial rescue implies additional effectors
  7. 2017 High

    Demonstrated a β-catenin-independent oncogenic function, with TCF7L1 overriding RAS-induced senescence in skin tumors via the downstream effector LCN2.

    Evidence Separation-of-function mutants, in vivo SCC/xenograft models, transcriptomics, and LCN2 rescue

    PMID:28467300

    Open questions at the time
    • Whether LCN2 is a direct TCF7L1 target not established
    • Mechanism of β-catenin-independent regulation unspecified
  8. 2018 Medium

    Extended β-catenin-independent activity to differentiation, showing TCF7L1 directly promotes cardiomyocyte fate, with activation-domain fusions retaining and repressor fusions lacking pro-cardiac activity.

    Evidence Temporally controlled expression in Tcf7l1-null ESCs with VP16/EnR/dN domain-swap constructs

    PMID:30326964

    Open questions at the time
    • Direct pro-cardiac target genes not identified
    • Single lab, limited replication
  9. 2017 Low

    Provided early evidence for TCF7L1 as a direct transactivator, activating Klf4 transcription independent of β-catenin binding.

    Evidence Overexpression and dnTcf7l1 mutant in Xenopus, Klf4 reporter, and cycloheximide treatment

    PMID:29336356

    Open questions at the time
    • Limited mechanistic depth; reporter-based in a single system
    • Endogenous direct binding at Klf4 not shown
  10. 2019 Medium

    Linked TCF7L1 to cancer stem cell self-renewal and revealed an IGF input, showing TCF7L1 represses Nanog and that MEK/ERK phosphorylation drives its degradation.

    Evidence Gain/loss in liver CSCs, Nanog repression assays, IGF pathway inhibition, and phosphorylation assays

    PMID:31322782

    Open questions at the time
    • ERK phosphosites on TCF7L1 not mapped
    • Crosstalk with β-catenin-driven degradation unresolved
  11. 2020 Medium

    Identified the kinase coupling β-catenin to TCF7L1 turnover, showing β-catenin recruits CK2 (Csnk2α1) to phosphorylate TCF7L1 and promote its degradation.

    Evidence CK2 inhibitors, Csnk2 gain/loss, reciprocal Co-IP, and protein-stability assays in mESCs

    PMID:31987502

    Open questions at the time
    • CK2 target phosphosites not defined
    • Link to a specific E3 ligase not established here
  12. 2023 Medium

    Resolved a degradation adaptor and an E3 ligase: Tbl1 shuttles to the nucleus with β-catenin to promote TCF7L1 ubiquitylation, and RNF2 ubiquitinates TCF7L1 to set Wnt signaling thresholds.

    Evidence Co-IP, ubiquitylation assays, fractionation/imaging, and protein-stability/reporter assays

    PMID:37957244 PMID:38639717

    Open questions at the time
    • Whether Tbl1, RNF2, and CK2 act in one pathway or in parallel is unresolved
    • Ubiquitin chain types and lysine targets unspecified
  13. 2023 High

    Mapped TCF7L1's role in early embryo fate decisions, showing it represses naive/formative pluripotency genes (Otx2, Lef1) to drive pluripotency exit and primitive endoderm specification.

    Evidence Time-series RNA-seq, promoter ChIP, and conditional knockout in mESCs and embryos

    PMID:36869101

    Open questions at the time
    • Cofactors directing PE-specific repression not identified
    • Relation to FoxA2/endoderm program in other contexts unintegrated
  14. 2023 Medium

    Expanded the direct CRC target repertoire and tissue roles, showing TCF7L1 represses LGR5 via a promoter-proximal WRE and controls intestinal tuft/secretory differentiation by restraining Notch effector Rbp-J.

    Evidence ChIP at LGR5 WRE with CRISPRa/i and rescue; conditional knockout mouse intestinal phenotyping

    PMID:36833408 PMID:37296573

    Open questions at the time
    • Mechanism of Rbp-J repression (direct vs indirect) unclear
    • How LGR5 repression integrates with stem-cell Wnt output untested
  15. 2024 Medium

    Defined additional CRC-relevant direct targets genome-wide, showing TCF7L1 represses GAS1 to promote migration, invasion, and adhesion.

    Evidence TCF7L1 ChIP-seq, transcriptomics, GAS1 rescue, and migration/invasion assays

    PMID:38816533

    Open questions at the time
    • Whether GAS1 repression is Wnt-dependent not addressed
    • Single lab
  16. 2024 Low

    Began cataloguing the chromatin-bound TCF7L1 interactome in human pluripotent cells.

    Evidence RIME endogenous chromatin IP-MS in hESCs

    PMID:38629187

    Open questions at the time
    • Single-method screen with no functional validation of novel partners
    • Partner identities not functionally placed in a pathway
  17. 2021 Medium

    Showed a context-specific activator role in prostate cancer, with TCF7L1 binding IL-8 and CXCR2 promoters upon WNT4 to drive neuroendocrine differentiation and motility.

    Evidence ChIP at IL-8/CXCR2 regulatory regions, gain/loss, WNT4 stimulation, and motility assays

    PMID:34799554

    Open questions at the time
    • What converts TCF7L1 from repressor to activator at these loci unknown
    • Cofactor dependence undefined
  18. 2024 Medium

    Introduced O-GlcNAcylation as a stabilizing modification, with O-GlcNAcylated TCF7L1 repressing androgen receptor to suppress prostate cancer.

    Evidence O-GlcNAcylation and stability assays, xenografts, and AR/EMT marker readouts

    PMID:41930151

    Open questions at the time
    • Modified residues not mapped
    • Whether AR repression is direct not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TCF7L1 switches between repressor and β-catenin-independent activator at specific loci, and how its multiple destabilization inputs (CK2, ERK, Tbl1, RNF2, O-GlcNAc) are integrated, remain unresolved.
  • No unified model linking the post-translational modifiers to specific degradation pathways
  • Determinants of activator versus repressor mode at individual targets unknown
  • No structural model of TCF7L1 on DNA with cofactors in the corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 6 GO:0003677 DNA binding 4
Localization
GO:0005634 nucleus 3 GO:0005694 chromosome 2
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-1643685 Disease 4 R-HSA-162582 Signal Transduction 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
CSNK2A1CTNNB1GROUCHOJMJD6RNF2TBL1X

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 β-catenin inactivates Tcf7l1 by removing it from DNA (rather than switching it to a coactivator complex), which leads to Tcf7l1 protein degradation. Mouse genetic experiments demonstrated that Tcf7l1 inactivation is the only required effect of the Tcf7l1–β-catenin interaction. Co-immunoprecipitation, DNA-binding assays, mouse genetic (knockout/knock-in) epistasis experiments Cell Reports High 23810553
2013 Tcf7l1 repressor activity is necessary in pluripotent epiblast cells for rapid lineage specification during gastrulation; Tcf7l1−/− embryos show delayed mesoderm specification uncoupled from primitive streak induction. Tcf7l1 knockout mouse analysis, embryo phenotyping, lineage marker analysis Development Medium 23487311
2015 Downstream of GSK3 inhibition, β-catenin reduces Tcf7l1 DNA binding (acting on protein) while elevated cMyc reduces Tcf7l1 mRNA levels; together they de-repress FoxA2, a pioneer factor for endoderm specification. Deletion of Tcf7l1 alone is sufficient to allow FoxA2 upregulation in the presence of Activin. GSK3 inhibitor treatment, Tcf7l1 knockout ESCs, chromatin immunoprecipitation, qRT-PCR, rescue experiments The EMBO Journal High 26675138
2015 Jmjd6 (a JmjC-domain protein) physically interacts with Tcf7l1 at the region responsible for Groucho corepressor binding, displacing Groucho and thereby de-repressing Tcf7l1 transcriptional targets; Jmjd6 antagonizes Tcf7l1 repressor activity and enhances β-catenin-induced gene activation in cells and Xenopus embryos. Co-immunoprecipitation (pulldown), reporter gene assays, Jmjd6 loss-of-function (morpholino), Xenopus embryo axis/gene-expression analysis Journal of Biological Chemistry Medium 26157142
2016 TCF7L1 functions as a transcriptional repressor that buffers β-catenin/TCF target gene expression in colorectal cancer; loss of TCF7L1 activates EPHB3 (a tumor suppressor/Paneth cell differentiation marker), and EPHB3 knockdown partially rescues growth of TCF7L1-null HCT116 cells. TCF7L1 knockdown/knockout in HCT116 CRC cells, mouse xenograft model, EPHB3 knockdown epistasis, colony formation and cell-cycle assays Scientific Reports Medium 27333864
2017 TCF7L1 promotes skin tumor growth and overrides oncogenic RAS-induced senescence independently of β-catenin interaction, using separation-of-function mutants. LCN2 was identified as a major downstream transcriptional effector of TCF7L1 driving tumor growth. Separation-of-function mutants (β-catenin-binding domain deleted), TCF7L1 overexpression/knockdown in mouse skin SCC model and xenograft, transcriptome profiling, LCN2 gain/loss-of-function assays eLife High 28467300
2018 Tcf7l1 directly promotes cardiomyocyte differentiation from ESCs in a β-catenin-independent manner; Tcf7l1-VP16 (activation domain fusion) and Tcf7l1dN (lacking β-catenin-binding domain) retain pro-cardiac activity, whereas Tcf7l1-En (repressor fusion) is ineffective. Temporally controlled Tcf7l1 expression in Tcf7l1-null ESCs, domain-swap fusion constructs (VP16, EnR, dN), cardiomyocyte differentiation assays Stem Cell Research & Therapy Medium 30326964
2019 Tcf7l1 transcriptionally represses Nanog in liver cancer stem cells (independently of β-catenin), attenuating their self-renewal. IGF signaling stimulates Tcf7l1 phosphorylation and protein degradation through the MEK/ERK pathway. Ectopic expression/knockdown in liver CSC populations, ChIP or reporter assays for Nanog repression, IGF pathway inhibition, phosphorylation assays Stem Cells Medium 31322782
2020 β-catenin recruits casein kinase 2 (CK2, specifically Csnk2α1) to phosphorylate Tcf7l1, promoting its protein degradation in mouse ESCs. CK2 inhibition blocks CHIR99021-induced Tcf7l1 reduction; Csnk2α1 physically interacts with Tcf7l1 and this interaction is enhanced by GSK3 inhibition. CK2 inhibitor treatment (TBB/DMAT), Csnk2 overexpression/knockdown, co-immunoprecipitation of Csnk2α1–Tcf7l1, protein stability assays in mESCs Biochemical and Biophysical Research Communications Medium 31987502
2021 TCF7L1 directly binds the regulatory sequences of IL-8 and CXCR2 promoters upon WNT4 activation, upregulating IL-8/CXCR2 signaling to drive neuroendocrine differentiation and cell motility in prostate cancer. ChIP at IL-8/CXCR2 regulatory regions, TCF7L1 gain/loss-of-function, WNT4 stimulation, cell motility assays Oncogenesis Medium 34799554
2023 TCF7L1 binds and represses naive pluripotency factor genes and formative pluripotency regulators (including Otx2 and Lef1), thereby driving pluripotency exit and primitive endoderm (PE) specification; Tcf7l1 deletion abrogates PE differentiation without restraining epiblast priming. Time-series RNA sequencing, promoter occupancy (ChIP), Tcf7l1 conditional knockout in mESCs and preimplantation embryos Nature Communications High 36869101
2023 RNF2 (an E3 ubiquitin ligase) ubiquitinates TCF7L1 and promotes its degradation upon Wnt signaling activation, destabilizing nuclear TCF7L1 to permit Wnt target gene transcription and controlling the threshold, persistence, and termination of Wnt signaling. RNF2 loss-of-function, ubiquitination assays, TCF7L1 protein stability measurements, Wnt target gene reporter assays Scientific Reports Medium 37957244
2023 TCF7L1 binds a promoter-proximal Wnt-responsive element (WRE) at the LGR5 locus via a consensus TCF binding element to repress LGR5 expression; restoring LGR5 rescues TCF7L1-mediated reduction in spheroid formation of CRC cells. ChIP (TCF7L1 binding at LGR5 WRE), TCF7L1 knockdown/overexpression, CRISPRa/i epigenetic modulation, spheroid formation rescue assays Genes Medium 36833408
2023 TCF7L1 promotes tuft cell differentiation in the adult small intestine and prevents precocious differentiation of embryonic intestinal progenitors; Tcf7l1 deficiency upregulates Notch effector Rbp-J, causing loss of embryonic secretory progenitors. Conditional Tcf7l1 knockout mice, intestinal epithelium phenotyping, marker analysis (tuft cell, secretory lineage, Notch pathway targets) Cells Medium 37296573
2024 Tbl1 (Tbl1x) physically interacts with Tcf7l1 and translocates from cytoplasm to nucleus with β-catenin upon GSK3 inhibition, acting as an adaptor to promote Tcf7l1 ubiquitylation and degradation in mESCs, thereby maintaining naïve pluripotency. Tblr1 affects Tcf7l1 levels but does not interact with it directly. Co-immunoprecipitation (Tbl1–Tcf7l1 interaction), Tbl1/Tblr1 overexpression and knockdown, ubiquitylation assays, subcellular fractionation/nuclear translocation imaging, mESC self-renewal assays Journal of Cell Science Medium 38639717
2024 A chromatin-associated TCF7L1 protein complex in human ESCs was characterized by RIME (rapid immunoprecipitation of endogenous proteins), identifying known and novel chromatin-bound partners of TCF7L1 in primed pluripotent cells. RIME (endogenous chromatin IP coupled to mass spectrometry) in hESCs Proteomics Low 38629187
2024 TCF7L1 represses GAS1 expression by binding its genomic locus; TCF7L1-mediated GAS1 repression promotes migration, invasion, and adhesion of colorectal cancer cells. TCF7L1 silencing/overexpression, genome-wide TCF7L1 ChIP-seq, transcriptome analysis, GAS1 rescue experiments, migration/invasion assays Scientific Reports Medium 38816533
2024 TCF7L1-mediated upregulation of HSPB6 suppresses the PI3K/AKT/mTOR signaling pathway in bladder cancer cells, inhibiting proliferation and metastasis. TCF7L1 overexpression/knockdown, RNA sequencing, western blot for PI3K/AKT/mTOR pathway components, cell proliferation and invasion assays Journal of Biological Chemistry Low 39608715
2026 O-GlcNAcylation of TCF7L1 (promoted by ONX-0914 activation of the hexosamine biosynthetic pathway) stabilizes TCF7L1 protein, which in turn transcriptionally represses androgen receptor (AR) expression to suppress prostate cancer progression. O-GlcNAcylation assays, protein stability assays, TCF7L1 overexpression in xenograft models, qPCR/western blot for AR and EMT markers Oncology Research Medium 41930151
2017 Tcf7l1 promotes transcription of Klf4 in early Xenopus embryos in a β-catenin-independent manner; a dominant-negative form of Tcf7l1 lacking the β-catenin binding motif still activates Klf4 transcription, and cycloheximide treatment showed a direct transcriptional effect. Tcf7l1 overexpression and dominant-negative mutant (dnTcf7l1) in Xenopus embryos, Klf4 promoter-reporter assay, cycloheximide treatment Journal of Biomedical Research Low 29336356
2014 Sox4 directly regulates Tcf7l1 transcription (identified by microarray and ChIP); Tcf7l1 is a key downstream effector of Sox4 in BCR-ABL+ ALL, as Tcf7l1 knockdown mimics Sox4 loss and ectopic Tcf7l1 rescues proliferation in Sox4-knockout leukemic cells. Microarray, ChIP (Sox4 binding at Tcf7l1 locus), Tcf7l1 knockdown, Sox4 knockout with Tcf7l1 ectopic rescue, in vitro and in vivo leukemia progression assays Haematologica Medium 24997151

Source papers

Stage 0 corpus · 28 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell reports 99 23810553
2013 Tcf7l1 prepares epiblast cells in the gastrulating mouse embryo for lineage specification. Development (Cambridge, England) 59 23487311
2016 TCF7L1 Modulates Colorectal Cancer Growth by Inhibiting Expression of the Tumor-Suppressor Gene EPHB3. Scientific reports 41 27333864
2015 Convergence of cMyc and β-catenin on Tcf7l1 enables endoderm specification. The EMBO journal 29 26675138
2023 The Wnt/TCF7L1 transcriptional repressor axis drives primitive endoderm formation by antagonizing naive and formative pluripotency. Nature communications 25 36869101
2014 The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica 24 24997151
2017 TCF7L1 promotes skin tumorigenesis independently of β-catenin through induction of LCN2. eLife 21 28467300
2019 Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of β-Catenin. Stem cells (Dayton, Ohio) 14 31322782
2015 JmjC Domain-containing Protein 6 (Jmjd6) Derepresses the Transcriptional Repressor Transcription Factor 7-like 1 (Tcf7l1) and Is Required for Body Axis Patterning during Xenopus Embryogenesis. The Journal of biological chemistry 14 26157142
2022 TCF7L1 Accelerates Smooth Muscle Cell Phenotypic Switching and Aggravates Abdominal Aortic Aneurysms. JACC. Basic to translational science 12 36908661
2021 TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer. Oncogenesis 11 34799554
2018 Tcf7l1 directly regulates cardiomyocyte differentiation in embryonic stem cells. Stem cell research & therapy 11 30326964
2019 Wnt suppressor and stem cell regulator TCF7L1 is a sensitive immunohistochemical marker to differentiate testicular seminoma from non-seminomatous germ cell tumor. Experimental and molecular pathology 10 31381875
2011 Tcf7l1 is required for spinal cord progenitor maintenance. Developmental dynamics : an official publication of the American Association of Anatomists 10 21932308
2013 Tcf7l1 proteins cell autonomously restrict cardiomyocyte and promote endothelial specification in zebrafish. Developmental biology 7 23707897
2024 TCF7L1 regulates colorectal cancer cell migration by repressing GAS1 expression. Scientific reports 6 38816533
2024 Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer. The Journal of biological chemistry 5 39608715
2023 TCF7L1 Regulates LGR5 Expression in Colorectal Cancer Cells. Genes 5 36833408
2024 miR-10167-3p targets TCF7L1 to inhibit bovine adipocyte differentiation and promote bovine adipocyte proliferation. Genomics 4 39069233
2020 β-catenin stimulates Tcf7l1 degradation through recruitment of casein kinase 2 in mouse embryonic stem cells. Biochemical and biophysical research communications 4 31987502
2023 TCF7L1 Controls the Differentiation of Tuft Cells in Mouse Small Intestine. Cells 2 37296573
2023 RNF2 regulates Wnt/ß-catenin signaling via TCF7L1 destabilization. Scientific reports 2 37957244
2025 Combined targeting of TCF7L1/2, PTEN, CDK6, and BCCIP by microRNA miR-29c-3p is associated with reduced invasion and proliferation of endometriotic cells. Reproductive medicine and biology 1 40135061
2024 Characterization of a chromatin-associated TCF7L1 complex in human embryonic stem cells. Proteomics 1 38629187
2024 Tbl1 promotes Wnt-β-catenin signaling-induced degradation of the Tcf7l1 protein in mouse embryonic stem cells. Journal of cell science 1 38639717
2023 Protective mechanism of TCF7L1 against retinal photoreceptor cell injury following retinitis pigmentosa based on the GEO database. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1 37000492
2017 Tcf7l1 promotes transcription of Kruppel-likefactor 4 during Xenopus embryogenesis. Journal of biomedical research 1 29336356
2026 ONX-0914 Suppresses Hormone-Sensitive Prostate Cancer by Promoting O-GlcNAcylation-Mediated Stabilization of TCF7L1. Oncology research 0 41930151

Missed literature

Know a paper Affinage missed for TCF7L1? Flag it for the maintainers and the community.

No submissions yet.